Objectives: To assess the value of empirical anti-Gram-positive antibiotics for the treatment of febrile neutropenia.
Introduction
Infection is a leading cause of death among cancer patients. Early antibiotic treatment reduces mortality and is standard practice for cancer patients with fever and neutropenia.
1,2 Selection of antibiotics is based on pathogen occurrences among these patients, and usually includes a b-lactam with broad-spectrum activity against Gram-negative organisms.
In the last few decades, the aetiology of infection among cancer patients has shifted from predominance of Gram-negative to that of Gram-positive bacteria. In multicentre trials conducted by the EORTC, the rate of Gram-positive infections increased from 29% of single-organism bacteraemias in 1973 to 69% in 1993. 3, 4 Increased use of indwelling catheters, quinolone prophylaxis, and mucositis induced by more intensive chemotherapy are implicated in these changes. 5 Currently used b-lactams do not provide adequate coverage for the majority of these Gram-positive infections.
Empirical antibiotic treatment was shown to reduce mortality when Gram-negative infections predominated, infections known to be rapidly fatal. 1 Empirical b-lactam monotherapy, holding broad-spectrum Gram-positive coverage, is currently considered safe despite the rising prevalence of resistant Gram-positive infections. Such practice must rely on evidence showing that mortality is not increased. We carried out a systematic review and meta-analysis of randomized trials assessing the empirical addition of antibiotics with specific activity against staphylococci and other Gram-positive bacteria.
Materials and methods

Inclusion criteria
We included randomized controlled trials comparing a standard antibiotic regimen ('standard') with or without the addition of an antibiotic with activity against Gram-positive bacteria ('intervention'). These were defined as: glycopeptides, 1st generation cephalosporins, penicillinase-resistant penicillins, clindamycin, quinupristin/dalfopristin, and linezolid. Any standard regimen was permitted as long as the same combination or monotherapy was used in both study arms. We included studies assessing empirical intervention, both initially ('initial therapy') and at the time of reassessment for persistent fever ('persistent fever'). Studies reporting efficacy analysis with a dropout rate after randomization above 30% were excluded. Studies are labelled by the first author and year of publication.
Search strategy
We used the search string: (neutrop?en* OR granulop?en* OR granulocytop?en * OR immune-supres * OR cancer * OR neoplasm * OR malignan* OR tumor* OR leukem* OR lymphom*), combined with specific antibiotic names and classes as defined above, and restricted to clinical trials. 
Outcomes
The primary outcome assessed was all-cause mortality at end of follow-up. Pre-defined secondary outcomes included overall failure disregarding treatment modifications; failure with modifications and the specific addition of amphotericin; durations of fever, treatment, and hospitalization. We extracted data on the development of resistance as well as the rates of bacterial and fungal superinfection and colonization. We extracted all adverse events and those resulting in treatment discontinuation or fatality.
Data extraction
Two reviewers independently extracted data from included trials. Missing data were sought for all trials and obtained for five. Outcomes were extracted by intention to treat, including all individuals randomized in the outcome assessment. When unavailable, data for available cases were used for the main comparisons, and their effect was assessed through sensitivity analysis.
Quality assessment
Two reviewers independently extracted randomization procedures, blinding, re-entries, intention-to-treat and the number of patients excluded from outcome assessment in studies reporting efficacy analysis. Allocation generation and concealment were classified as A (adequate); B (unclear); C (inadequate), using criteria suggested in the Cochrane handbook. 7 We carried out sensitivity analyses for allocation concealment, based on evidence showing overestimation of effects with inadequate allocation concealment.
8,9
Data analysis
Relative risks (RRs) with 95% confidence intervals are reported. Treatment effects across studies were combined using the fixed effect model. The Z statistic was used to test for a significant pooled estimate (i.e. significantly different than 1 at a 95% confidence level). The fixed effect model assumes a common effect for all studies. Heterogeneity was assessed using a x 2 test for heterogeneity (Cochran's Q test), and the I 2 statistic. 10 The I 2 statistic estimates the percentage of the variability in effect estimates that is due to heterogeneity rather than chance alone, with values > 50% indicating substantial heterogeneity. We carried out subgroup analyses of patients with documented Gram-positive infections. While studies report rates of Gram-positive bacteraemia, outcomes for these patients are usually not reported. We therefore used meta-regression to assess the association between the incidence of Gram-positive bacteraemia and individual study effect estimates (STATA 8 software). Regression coefficients are the estimated increase in the log risk ratio per unit-increase in the covariate, in this case the incidence of Gram-positive bacteraemia. Relative risk ratios (RRR) with 95% confidence intervals are reported. A funnel plot (standard error plotted against odds ratios) was examined to estimate potential selection bias (publication or other), or discrepancies between large and small studies. Allocation concealment methods: A, adequate, if participants and the investigators enrolling participants could not foresee assignment. Adequate methods include a priori numbered or coded drug containers of identical appearance prepared by an independent pharmacy; central randomization carried out at a site remote from trial location; and sequentially numbered, sealed, opaque envelopes. B, unclear, if the method was not described. Allocation generation methods: A, adequate, if the method used is described and the resulting sequences are unpredictable. Adequate methods include computer generated random numbers, table of random numbers, and drawing of lots or envelopes. B, unclear, if the trial was described as randomized, but the method used for the allocation sequence generation was not described.
Results
We scanned 331 abstracts of which 41 publications were considered for further evaluation ( Figure 1 ). Twenty-one were excluded and seven represented double publications. Two studies were excluded on account of a high percentage of dropouts. An EORTC trial randomized 841 patients and evaluated 419 patients. 29 Martino et al. reported outcomes for a 10 month period and 158 patients, of a trial which was conducted for 15 months and included 232 patients.
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Thirteen trials, randomizing 2392 participants, fulfilled inclusion criteria (Table 1) . Eleven studies assessed the 'initial' empirical treatment of fever and neutropenia. The antibiotics evaluated were glycopeptides (seven studies), cefalothin (2), flucloxacillin (1), and trimethoprim/sulfamethoxazole (1). Studies assessing glycopeptides were completed between the years 1984 and 1992, while studies assessing other antibiotics were completed before 1985. Two studies, assessing glycopeptides, tested their addition for 'persistent fever' after 72 to 96 h of standard treatment. The standard antibiotic regimens are detailed in Table 1 . The two 'persistent fever' studies excluded patients with catheter-related infections, 50, 51 and another trial excluded patients with any obvious source of infection.
45 None of the studies specified septic shock as an exclusion criterion, and all permitted antibiotic prophylaxis before randomization. The rate of single Gram-positive bacteraemia varied from 5.6% to 28.3%. It did not correlate with study year as expected, possibly due to the differing locations and inclusion criteria of the studies included in the review.
Eleven trials described randomization procedures and all were adequately randomized, with adequate allocation concealment described in eight ( Table 1 ). The two studies assessing the addition of glycopeptides for persistent fever were adequately randomized, concealed and double-blinded.
All-cause mortality
No significant difference in all-cause mortality was seen with the addition of antibiotics against Gram-positive infections [RR 0.86 (0.58 -1.26), values < 1 favouring the intervention, Figure 2 ]. Seven studies and 852 participants were assessed. Two studies assessed 'initial' glycopeptides, two assessed their addition for 'persistent fever', and three trials examined the 'initial' addition of other anti-Gram-positive antibiotics. No difference was seen for each sub-category. Heterogeneity was observed between the two studies assessing additional glycopeptides for persistent fever (P = 0.15, I 2 = 50.7%), but the overall comparison was non-heterogeneous (P = 0.83, I 2 = 0%). Six studies including 1420 participants reported infectionrelated mortality. No difference was seen overall [RR 1.18 (0.72 -1.92), I 2 = 0%]. The sub-category of additional empirical glycopeptides included four studies, of which two did not report overall mortality, and no difference was observed within this sub-category either [RR 1.16 (0.62-2.17), 1030 participants,
Four studies were not included in the mortality analyses. Three provided no information, 41, 43, 46 and the authors of one reported no significant difference in mortality without providing data. 40 Only four studies reported all-cause mortality for patients with documented Gram-positive infections. No significant difference was detected [RR 2.15 (0.56 -8.25), 107 participants]. Comparative data for other subgroups were scarce (Grampositive bacteraemia, one study, 26 participants; Staphylococcus aureus infections, two studies, 15 participants; streptococcal infections, three studies, 53 participants), and no significant difference was found for any of the comparisons.
There was no association between the rate of single-agent Gram-positive bacteraemia and the relative risk for mortality. No consistent data were available for development of resistance, colonization, and for time to event outcomes.
Adverse events
Addition of anti-Gram-positive treatment resulted in significantly more adverse events (Table 2) , mostly dermatological. Glycopeptides were associated with increased nephrotoxicity resulting in harm caused to one of every 37 patients given a glycopeptide.
Sensitivity analyses and selection bias
Repeating the analyses for all-cause mortality and treatment failure using only studies with adequate allocation concealment did not affect results (data not shown). No significant difference in all-cause mortality was seen when analysis was restricted A funnel plot (not shown) showed a symmetric distribution of the studies.
Discussion
The pathogen shift among neutropenic cancer patients towards resistant Gram-positive infections raises the concern whether antibiotics targeting these infections need be added to the empirical treatment of these patients. Current practice is based on results from individual studies that show no advantage to the empirical administration of glycopeptides. These studies are relatively small and may be underpowered to detect differences, particularly in mortality, which is a rare event but the most significant outcome of sepsis. We therefore combined all evidence available from randomized trials assessing the addition of antiGram-positive antibiotics.
The empirical addition of antibiotics against Gram-positive infections did not reduce all-cause mortality [RR 0.86 (0.58-1.26)]. In unblinded studies, more treatment modifications were made in the control arm, but overall success was equally achieved. Infection-related mortality did not differ between the study groups. More Gram-positive superinfections were detected in the control arm, but the effects of additional glycopeptides on colonization with resistant microorganisms or selection of resistance could not be assessed. Adverse events were more frequent in the intervention arm, which included an increased rate of nephrotoxicity when the additional antibiotic was a glycopeptide. Thus, no advantage to empirical use of antibiotics against Gram-positive infections was detected, but for a lower rate of Gram-positive superinfections with inadequate data to assess the overall effect of empirical glycopeptides on future resistance.
To maximize our power to detect a significant difference, we merged studies assessing both the initial and the later addition of glycopeptides, and studies assessing other antibiotics with Grampositive spectra. All studies are empirical in that the intervention was implemented before detection of a causative pathogen. All Systematic Review compared a standard antibiotic regimen to the same regimen, combined with specific antibiotics against Gram-positive infections. These changed throughout the years mirroring changes in the prevalence of resistant Gram-positive infections. Currently, only 51.6% of Gram-positive infections among febrile neutropenic patients are susceptible to b-lactams in different cancer centres in the USA. 52 Thus, the antibiotics chosen nowadays for which our results apply are glycopeptides.
The relative risk for mortality favours additional anti-Grampositive treatment, but the 95% confidence intervals include equivalence and superiority of the control regimen. Figure 2 shows that the advantage to the intervention largely originates from earlier studies using non-glycopeptide antibiotics. To further assess the existence of a possible benefit for additional anti-Gram-positive antibiotics, we repeated outcome analyses for patients in whom Gram-positive infections were subsequently documented. No advantage was detected in these patients as well. Neither did we find a significant relationship between increasing rates of Gram-positive bacteraemia and improved outcomes.
The major limitation of this study is the rather small number of studies identified, some of which did not provide comparative data for all-cause mortality. Only two studies assessed the empirical addition of glycopeptides for persistent fever, and their results regarding mortality point in opposite directions. Five trials permitted patient re-inclusion referring to febrile episodes instead of patients. This is methodologically incorrect since the statistical tests used assume independence between observations. Finally, our study cannot exclude the possibility that selected patients may benefit from empirical glycopeptides.
Elting et al. analysed 909 episodes of bacteraemia using primary data from 10 randomized clinical trials of initial empirical therapy for febrile neutropenia. 19 The presence of septic shock at onset and clinically documented infections were associated with a significantly higher mortality rate due to infection (P < 0.0001 for both in multivariate analysis). Septic shock complicated only 1% of bacteraemias due to Gram-positive organisms compared with 5% of Gram-negative bacteraemias, but mortality of patients with septic shock reached 59%, with only two of 22 patients for whom initial therapy failed surviving long enough to permit modification of therapy. Empirical glycopeptides are recommended for these patients. 2 Patients with clinically documented infections faired poorly. Intensive aetiological investigation should be carried out in these patients to direct therapy, including the need for additional glycopeptides.
In the same study, the initial administration of vancomycin was not associated with improved ultimate outcome for patients with Gram-positive bacteraemia (418 patients), with the exception of Streptococcus viridans bacteraemia (117 patients). In these patients, initial administration of vancomycin was associated with a 14% absolute reduction in mortality (P = 0.004). This study and current guidelines 2 suggest that centres in which these Gram-positive bacteria are common causes of serious infections, or are commonly associated with penicillin resistance, should consider empirical use of glycopeptides. Other risk factors for viridans streptococcal bacteraemia identified by multivariate analyses in different trials include profound neutropenia, oral mucositis, high dose cytosine arabinoside therapy, prophylaxis with trimethoprim/sulfamethoxazole or fluoroquinolones, and use of antacids or histamine type 2 blockers. 53 The presence of one or more of these factors should prompt a careful assessment for the need of empirical glycopeptide therapy.
Catheter-related infections and skin/soft-tissue infections are most commonly caused by Gram-positive bacteria. Centres in which resistance to b-lactams is prevalent should use glycopeptides empirically for these infections. 2 In summary, currently available evidence from randomized controlled trials does not support the need for empirical glycopeptides initially or for persistent fever. Withholding specific treatment against Gram-positive infections pending growth of a resistant Gram-positive organism is safe. Despite more frequent treatment modifications, such practice is associated with fewer adverse events.
Cancer centres need to monitor pathogen prevalences to guide empirical treatment. Future trials assessing empirical glycopeptides are warranted if the spectrum of infections in cancer patients progresses further towards Gram-positive infections. Such trials should adhere to recommendations for their design, analysis and reporting. 54, 55 14. Dompeling, E. C., Donnelly, J. P., Deresinski, S. 
